TC Biopharm (Holdings) PLC (TCBPY) Tài chính

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 39 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified GD-T cell product line - phase IIb/III pivotal trial in treatment of AML using its allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product candidate, OmnImmune is an unmodified allogeneic GD-T cell product, being initially used for the treatment of AML. Its pre-clinical stage program is focused on developing CAR-modified allogeneic GD-T cell products targeting solid and hematological indications. The company has an Israeli patent and Japanese patent applications covering the method of preparing and using GD-T cells in the allogeneic treatment of subjects suffering from viral, fungal and protozoal infections or cancer.